Erratum: Persistence of bactericidal antibodies after infant serogroup b meningococcal immunization and booster dose response at 12, 18 or 24 Months of Age(Pediatric Infectious Disease Journal (2016) 35 (e113–e123) DOI: 10.1097/INF.0000000000001056);Persistence of bactericidal antibodies after infant serogroup B meningococcal immunization and booster dose response at 12, 18 or 24 months of age

Pediatric Infectious Disease Journal

Volumn 35, Issue 4, 2016, Pages e113-e123

  Snape, Matthew D ^a,b   Voysey, Merryn ^a   Finn, Adam ^c   Bona, Gianni ^d   Esposito, Susanna ^e   Principi, Nicola ^e   Diez Domingo, Javier ^f   Sokal, Etienne ^g   Kieninger, Dorothee ^h   Prymula, Roman ⁱ   Dull, Peter M ^j   Kohl, Igor ^j,k   Barone, Michelangelo ^k   Wang, Huajun ^l   Toneatto, Daniela ^k   Pollard, Andrew J ^a   Heath, Paul T ^m   Oeser, Clarissa ^m   Collinson, Andrew ⁿ   Heslop, Jasmine ⁿ   John, Tessa ^a   Kelly, Sarah ^a   De Martino, Maurizio ^o   Galli, Luisa ^o   Azzari, Chiara ^ap   Bianchi, Leila ^ap   Giaquinto, Carlo ^p   Masiero, Susanna ^p   Zuccotti, Gianvincenzo ^q   Ghezzi, Benedetta ^k   Baehner, Frank ^k   Nasemann, Carina ^k   Inzillo, Simone ^k   Belli, Riccardo ^k   Hlavata, Lucie ^k   Grasso, Nicolino ^d   Cabañero, Miguel A ^r   Suárez, Eva ^s   Peñarroja, Susana ^t   Antón, Vicente ^u   Martínez, Manolo ^v   Garcés, María D ^u   Jubert, Angels ^w   Asensi, Maite ^x   Sorribes, Ignacio ^y   Úbeda, Isabel ^z   Planelles, Victoria ^aa   Villarroya, Jose ^ab   Tortajada Gribes Md, Miguel ^ac   Martinón Torres, Federico ^ad   Collazo, Lorenzo Redondo ^ad   Rodriguez, Julián S ^ae   Vertruyen, André ^af   Ramet, Jose ^ag   Verghote, Marc ^ah   Raes, Marc ^ai   Malfroot, Anne ^aj   Behre, Ulrich ^ak   Kimmig, Martin ^ak   Knecht, Roland ^ak   Schlegel, Dieter ^ak   Simmet, Siegfried ^ak   Steiner, Michael ^ak   Sandner, Bernhard ^ak   Weh, Martina ^ak   Ziegler Kirbach, Eckhard ^ak   Kaiser, Friedrich ^ak   Bleckmann, Gerhard ^ak   Adelt, Thomas ^ak   Köllges, Ralph ^ak   Pankow Culot, Heidemarie ^ak   Soemantri, Peter ^ak   Von Feldegg, Philip Fellner ^ak   Hauptmann, Dietmar ^ak   Weishaar, Christian ^ak   Achtzehn, Roland ^ak   Horn, Christian ^ak   Schäfer, Christoph ^ak   Wilmsmeyer, Brigitte ^ak   Franke Beckmann, Eivy ^ak   Chlíbek, Roman ^al   Němec, Vladimír ^am   Týce, Luděk ^an   Dražan, Daniel ^ao   more..

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b NIHR OXFORD BIOMEDICAL RESEARCH CENTRE   (United Kingdom)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

^d ALS Center   (Italy)

^e UNIVERSITY OF MILAN   (Italy)

^f Area of Vaccines Research   (Spain)

^g CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^h UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

ⁱ CHARLES UNIVERSITY   (Czech Republic)

^j Novartis Vaccines and Diagnostics Inc   (United States)

^k NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

^l Research and Development   (Netherlands)

^m ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

ⁿ NATIONAL HEALTH SERVICE   (United Kingdom)

^o UNIVERSITY OF FLORENCE   (Italy)

^p UNIVERSITY OF PADOVA   (Italy)

^q UNIVERSITY OF MILAN   (Italy)

^r Centro de Salud San Agustín   (Spain)

^s Centro de Salud Almassora   (Spain)

^t Centro de Salud Vall D'Uixo   (Spain)

^u Centro de Salud Nazaret   (Spain)

^v Centro de Salud Republica Argentina   (Spain)

^w Centro de Salud Malvarrosa   (Spain)

^x Centro de Salud Serreria i   (Spain)

^y Centro de Salud Serreria II   (Spain)

^z Centro de Salud de la Eliana   (Spain)

^aa Centro de Salud Paiporta   (Spain)

^ab rea de Salud de Segovia   (Spain)

^ac Centro de Salud Catarroja   (Spain)

^ad University Hospital of Santiago de Compostela   (Spain)

^ae HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^af Sint Vincentius   (Belgium)

^ag ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^ah Centre Hospitalier Regional de Namur   (Belgium)

^ai Virga Jesse Ziekenhuis   (Belgium)

^aj UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^ak NETSTAP EV   (Germany)

^al UNIVERSITY OF DEFENCE   (Czech Republic)

^am Children's Department Pardubice   (Czech Republic)

^an Detske Stredisko   (Czech Republic)

^ao Petrovice U Karvine   (Czech Republic)

^ap Children's Department Pardubice ^*

more..

Author keywords

Paediatric; Persistence of immunity; Serogroup B meningococcal vaccine; Serum bactericidal activity

Indexed keywords

BACTERIUM ANTIBODY; CHICKENPOX VACCINE; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HEPATITIS B VACCINE; MEASLES MUMPS RUBELLA VACCINE; MENINGOCOCCUS VACCINE; PNEUMOCOCCUS VACCINE;

ANTIBODY RESPONSE; ANTIBODY TITER; AUTISM; BACTERIAL STRAIN; CHICKENPOX; CONFERENCE PAPER; CONTROLLED STUDY; DIPHTHERIA; DOSE RESPONSE; FEBRILE CONVULSION; FEMALE; FEVER; GENERALIZED EPILEPSY; HAEMOPHILUS INFLUENZAE; HEPATITIS B; HUMAN; IMMUNIZATION; IMMUNOGENICITY; INFANT; INFLUENZA B; INJECTION SITE REACTION; LEARNING DISORDER; MALE; MEASLES; MENINGOCOCCOSIS; MULTICENTER STUDY; MUMPS; OPEN STUDY; PERTUSSIS; PHASE 2 CLINICAL TRIAL; PNEUMOCOCCAL INFECTION; POLIOMYELITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RUBELLA; SEROTYPE; SERUM BACTERICIDAL ACTIVITY; SPEECH DELAY; TREATMENT OUTCOME; VIRUS PNEUMONIA; BLOOD; CLINICAL TRIAL; EUROPE; IMMUNOLOGY; MENINGITIS, MENINGOCOCCAL; NEISSERIA MENINGITIDIS; OUTCOME ASSESSMENT; PRESCHOOL CHILD; SECONDARY IMMUNIZATION; VACCINATION;

ANTIBODIES, BACTERIAL; CHILD, PRESCHOOL; EUROPE; FEMALE; HUMANS; IMMUNIZATION SCHEDULE; IMMUNIZATION, SECONDARY; INFANT; MALE; MENINGITIS, MENINGOCOCCAL; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS, SEROGROUP B; OUTCOME ASSESSMENT (HEALTH CARE); VACCINATION;

EID: 84954341933     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0000000000002754     Document Type: Erratum

References (31)

1. FDA approves a second vaccine to prevent serogroup B meningococcal disease 2015. Available at: http://www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/ucm431370.htm. Accessed February 11, 2015.
2. Assessment report: Bexsero. Committee for Medicinal Products for Human Use, European Medicines Agency, 2013 Contract No.: EMA/790069/2012.
3. Operation Reussie. Premier vague de vaccination contre le meningococoque de serogroup B. Agence de la sante et des services sociaux du Saguenay-Lac-Saint-Jean 2014. Available at: http://www.csrsaguenay.qc.ca/ medias/csrsaguenay/fichiers/Actualite/Communique-fin-campagne-printemps- 140618-3.pdf. Accessed on October 6, 2104.
4. JCVI position statement on the use of Bexsero meningococcal vaccine in the UK 2014. Available at: https://http://www.gov.uk/government/publications/ meningococcal-b-vaccine-jcvi-position-statement. Accessed June 13, 2015.
5. Meningitis B vaccine deal agreed - Jeremy Hunt 2015. Available at: http:// www.bbc.co.uk/news/health-32101921. Accessed on April 25, 2015.
6. Auckland C, Gray S, Borrow R, et al. Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the United Kingdom. J Infect Dis. 2006;194:1745-1752.
7. Galloway Y, Stehr-Green P, McNicholas A, et al. Use of an observational cohort study to estimate the effectiveness of the New Zealand group B meningococcal vaccine in children aged under 5 years. Int J Epidemiol. 2009;38:413-418.
8. Jackson C, Lennon D, Wong S, et al. Antibody persistence following MeNZB vaccination of adults and children and response to a fourth dose in toddlers. Arch Dis Child. 2011;96:744-751.
9. Holst J, Feiring B, Fuglesang JE, et al. Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease. Vaccine. 2003;21:734-737.
10. Gossger N, Snape MD, Yu LM, et al; European MenB Vaccine Study Group. Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial. JAMA. 2012;307:573-582.
11. Snape MD, Saroey P, John TM, et al. Persistence of bactericidal antibodies following early infant vaccination with a serogroup B meningococcal vaccine and immunogenicity of a preschool booster dose. CMAJ. 2013;185:E715-E724.
12. Frasch CE, Borrow R, Donnelly J. Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease. Vaccine. 2009;27 (suppl 2):B112-B116.
13. Findlow J, Borrow R, Snape MD, et al. Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin Infect Dis. 2010;51:1127-1137.
14. ClinicalTrials.gov. Investigating the immune response to 4CMenB in infants. NCT02080559 2014. Available at: http://www.clinicaltrials.gov/ct2/ show/NCT02080559?term=euclids+oxford&rank=1. Accessed on May 5, 2014.
15. Surveillance of invasive bacterial diseases in Europe 2011; 2013. Available at: http://www.ecdc.europa.eu/en/publications/Publications/invasive-bacterial-diseases-surveillance-2011.pdf. Accesses on February 11, 2015.
16. ClinicalTrials.gov. Persistence of antibody levels and response to fifth or third meningococcal B recombinant vaccine in 4-year old healthy children Who previously participated in study V72P12E1. NCT01717638. Available at: http://www.clinicaltrials.gov/ct2/show/NCT01717638?term=v72P12&r ank=1. Accessed on May 5, 2014.
17. European Medicines Agency. Summary of Product characteristics: Bexsero 2013. Available at: http://www.ema.europa.eu/docs/en-GB/document- library/EPAR-Product-Information/human/002333/WC500137881.pdf. Accessed May 8, 2013.
18. Snape MD, Klinger CL, Daniels ED, et al. Immunogenicity and reactogenicity of a 13-valent-pneumococcal conjugate vaccine administered at 2, 4, and 12 months of age: a double-blind randomized active-controlled trial. Pediatr Infect Dis J. 2010;29:e80-e90.
19. Pace D, Snape M, Westcar S, et al. A novel combined Hib-MenC-TT glycoconjugate vaccine as a booster dose for toddlers: a phase 3 open randomised controlled trial. Arch Dis Child. 2008;93:963-970.
20. Richmond P, Borrow R, Goldblatt D, et al. Ability of 3 different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlers. J Infect Dis. 2001;183:160-163.
21. Public Health England. Supply or administration of paracetamol oral suspension 120 mg/5 mL to infants under 12 months of age receiving primary doses of Men B vaccination. 2015. Available at: https://www. gov.uk/government/uploads/system/uploads/attachment-data/file/453 782/20150811PHEParacetamolProtocolFinalv01-00.pdf. Accessed on September 1, 2015.
22. Vesikari T, Esposito S, Prymula R, et al. Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials. Lancet. 2013;381: 825-835.
23. Snape MD, Philip J, John TM, et al. Bactericidal antibody persistence 2 years after immunization with 2 investigational serogroup B meningococcal vaccines at 6, 8 and 12 months and immunogenicity of preschool booster doses: a follow-on study to a randomized clinical trial. Pediatr Infect Dis J. 2013;32:1116-1121.
24. McQuaid F, Snape MD, John TM, et al. Persistence of bactericidal antibodies to 5 years of age after immunization with serogroup B meningococcal vaccines at 6, 8, 12 and 40 months of age. Pediatr Infect Dis J. 2014;33: 760-766.
25. Santolaya ME, O'Ryan M, Valenzuela MT, et al. Persistence of antibodies in adolescents 18-24 months after immunization with one, two, or three doses of 4CMenB meningococcal serogroup B vaccine. Hum Vaccin Immunother. 2013;9:2304-2310.
26. Snape MD, Kelly DF, Lewis S, et al. Seroprotection against serogroup C meningococcal disease in adolescents in the United Kingdom: observational study. BMJ. 2008;336:1487-1491.
27. McQuaid F, Snape MD, John TM, et al. Persistence of specific bactericidal antibodies at 5 years of age after vaccination against serogroup B meningococcus in infancy and at 40 months. CMAJ. 2015;187:E215-E223.
28. JCVI interim position statement on use of Bexsero meningococcal B vaccine in the UK; July 2013. Available at: https://http://www.gov.uk/ government/uploads/system/uploads/attachment-data/file/224896/JCVI- interim-statement-on-meningococcal-B-vaccination-for-web.pdf. Accessed on May 6, 2014.
29. Borrow R. Issues in evaluating the impact of a new meningococcal B vaccine. Meningitis Symposium. Bristol: Meningitis Research Foundation; 2013.
30. Centres for Disease Control and Prevention. Princeton University Meningococcal Disease Outbreak 2014. Available at: http://www.cdc.gov/ meningococcal/outbreaks/princeton.html. Accessed May 6, 2014.
31. Centres for Disease Control and Prevention. University of California, Santa Barbara Meningococcal Disease Outbreak 2014. Available at: http://www. cdc.gov/meningococcal/outbreaks/ucsb.html. Accessed on May 6, 2014.